3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
9
Recruiting
8
Unknown
3
Terminated
2
Active not recruiting
2
Withdrawn
1
Approved for marketing
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Ovarian Neoplasms
5
Triple Negative Breast Neoplasms
2
Sarcoma
2
Prostatic Neoplasms
2
Breast Neoplasms
2
Uveal Melanoma
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Platinum-Refractory Fallopian Tube Carcinoma
1
Pancreatic Neoplasms
1
Neoplasms
1
Melanoma
1
Lymphoma
1
Liposarcoma
1
Fallopian Tube Neoplasms
1
Carcinoma, Squamous Cell
1
Anatomic Stage III Breast Cancer AJCC v8
1
Interventions
Cisplatin
9
pembrolizumab
7
Radiosurgery
6
Gemcitabine
6
Paclitaxel
5
Dexamethasone
5
Taxes
4
Carboplatin
4
trametinib
3
ibrutinib
3
Surveys and Questionnaires
3
Standard of Care
3
Radiotherapy
3
Nivolumab
3
Magnetic Resonance Spectroscopy
3
Lenalidomide
3
Fluorouracil
3
Erlotinib Hydrochloride
3
Blood Specimen Collection
3
Ascorbic Acid
3
venetoclax
2
veliparib
2
tocilizumab
2
pazopanib
2
obinutuzumab
2
naquotinib
2
lenvatinib
2
fludarabine
2
enzalutamide
2
Vemurafenib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Neoplasms
×
olaparib
×
Clear all
NCT06116578
2025-12-01
NeoSarc
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2
Withdrawn